IRC-082451, a Novel Multitargeting Molecule, Reduces L-DOPA-Induced Dyskinesias in MPTP Parkinsonian Primates

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Aron Badin, Romina ^a,b   Spinnewyn, Brigitte ^c   Gaillard, Marie Claude ^a,b   Jan, Caroline ^a,b   Malgorn, Carole ^a,b   van Camp, Nadja ^a,b   Dollé, Frédéric ^d   Guillermier, Martine ^a,b   Boulet, Sabrina ^e,f   Bertrand, Anne ^e   Savasta, Marc ^e,f,g   Auguet, Michel ^c   Brouillet, Emmanuel ^a,b   Chabrier, Pierre Etienne ^c   Hantraye, Philippe ^a,b  

^a Molecular Imaging Research Center   (France)

^b SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^c IPSEN   (France)

^d SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^e GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

^f UNIV GRENOBLE ALPES   (France)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CENTRAL NERVOUS SYSTEM AGENTS; DOPAMINE; IRC 082451; MESSENGER RNA; PROTEIN C FOS; TRANSCRIPTION FACTOR FOSB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARC GENE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINE METABOLISM; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG RESPONSE; DRUG SCREENING; DYSKINESIA; FOSB GENE; GENE; GENE LOCATION; ISOTOPE LABELING; LOCOMOTION; LONG TERM EXPOSURE; MALE; NONHUMAN; ONCOGENE C FOS; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PUTAMEN;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AMANTADINE; ANIMALS; ANTIOXIDANTS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DYSKINESIAS; IMMUNOHISTOCHEMISTRY; LEVODOPA; MACACA FASCICULARIS; MAGNETIC RESONANCE IMAGING; MALE; NEURONS; OXIDATIVE STRESS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; THIAZOLES;

ANIMALIA; PARKINSONIA; PRIMATES;

EID: 84871887001     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052680     Document Type: Article

References (45)

1. de Lau LM, Breteler MM, (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5: 525-535.
2. Cotzias GC, Papavasiliou PS, Gellene R, (1969) Modification of Parkinsonism-chronic treatment with L-dopa. N Engl J Med 280: 337-345.
3. Marsden CD, (1994) Parkinson's disease. J Neurol Neurosurg Psychiatry 57: 672-681.
4. Chase TN, (1998) Levodopa therapy: consequences of the non physiologic replacement of dopamine. Neurology 50: S17-S25.
5. Rascol O, Fabre N, (2001) Dyskinesia: L-dopa-induced and tardive dyskinesia. Clin Neuropharmacol 24: 313-323.
6. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, et al. (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.Proc Natl Acad Sci USA. 80: 4546-4550.
7. Langston JW, Langston EB, Irwin I (1984) MPTP-induced parkinsonism in human and non-human primates-clinical and experimental aspects. Acta Neurol Scand Suppl 100: 49-54.
8. Hantraye P, Varastet M, Peschanski M, Riche D, Cesaro P, et al. (1993) Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience 53: 169-178.
9. Varastet M, Riche D, Maziere M, Hantraye P, (1994) Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease. Neuroscience 63: 47-56.
10. Bezard E DS, Bioulac B, Gross CE, (1997) Kinetics of nigral degeneration in a chronic model of MPTP-treated mice. Neurosci Lett 234: 3.
11. Bezard E, Imbert C, Gross CE, (1998) Experimental models of Parkinson's disease: from the static to the dynamic. Rev Neurosci 9: 71-90.
12. Schmidt N, Ferger B, (2001) Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm 108: 1263-1282.
13. Blanchet PJ, Calon F, Morissette M, Hadj Tahar A, Bélanger N, et al. (2004) Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism Relat Disord 10: 297-304.
14. Bédard PJ, Blanchet PJ, Lévesque D, Soghomonian JJ, Grondin R, et al. (1999) Pathophysiology of L-dopa-induced dyskinesias. Mov Disord 14S1: 4-8.
15. Hadj Tahar A, Grondin R, Grégoire L, Calon F, Di Paolo T, et al. (2003) New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable. Adv Neurol 91: 51-64.
16. Chabrier PE, Auguet M, (2007) Pharmacological properties of BN82451: a novel Multitargeting neuroprotective agent. CNS Drug Rev 13: 317-332.
17. Spinnewyn B, Mautino G, Marin JG, Rocher MN, Grandoulier AS, et al. (2011) BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Neuropharmacology 60: 692-700.
18. Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, et al. (2001) Intravenous amantadine improves levodopa-induced dyskinesias: an acute double-blind placebo controlled study. Mov Disord 16: 515-520.
19. da Silva-Junior FP, Braga-Neto P, Sueli Monte F, de Bruin VM, (2005) Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord 11: 449-452.
20. Sawada H, Oeda T, Kuno S, Nomoto M, Yamamoto K, et al. (2010) Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. PLoS One 5: e15298.
21. Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, et al. (2010) Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord 25: 1357-1363.
22. Church JS, Martz DG, Cook NJ, (2006) The use of digital video recorders (DVRs) for capturing digital video files for use in both The Observer and Ethovision. Behav Res Methods 38: 434-438.
23. Walton A, Branham A, Gash DM, Grondin R, (2006) Automated video analysis of age-related motor deficits in monkeys using EthoVision. Neurobiol Aging 27: 1477-1483.
24. Jarraya B, Boulet S, Ralph GS, Jan C, Bonvento G, et al. (2009) Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci Transl Med 14 1: 2ra4.
25. Papa SM, Chase TN, (1996) Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann. Neurol 39: 574-578.
26. Obeso JA, Olanow CW, Nutt JG, (2000) Levodopa motor complications in Parkinson's disease. Trends Neurosci 23: S2-7.
27. Shin M, Jan C, Jacquard C, Jarraya B, Callebert J, et al. (2011) Chronic systemic treatment with a high-dose proteasome inhibitor in mice produces akinesia unrelated to nigrostriatal degeneration. Neurobiol Aging 32: 2100-2102.
28. Patlak CK, Blasberg RG, (1985) Graphical evaluation of blood-to-brain transfer constants multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 5: 584-590.
29. Poyot T, Condé F, Grégoire MC, Frouin V, Coulon C, et al. (2001) Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa. J Cereb Blood Flow Metab 21: 782-792.
30. Blanchet PJ, Konitsiotis S, Chase TN, (1998) Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 13: 798-802.
31. Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, et al. (2004) Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-mthyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. JPET 310: 386-394.
32. Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, et al. (2005) Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp Neurol 196: 422-429.
33. Kobylecki C, Hill MP, Crossman AR, Ravenscroft P, (2001) Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease. Mov Disord 26: 2354-2363.
34. Koprich JB, Fox SH, Johnston TH, Goodman A, Le Bourdonnec B, et al. (2011) The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease. Mov Disord 26: 1225-1233.
35. Schneider JS, Pope-Coleman A, Van Velson M, Menzaghi F, Lloyd GK, (1998) Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys. Mov Disord 13: 637-642.
36. Iravani MM, Jackson MJ, Kuoppamäki M, Smith LA, Jenner P, (2003) 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Neurosci 23: 9107-9115.
37. Konradi C, Westin JE, Carta M, Eaton ME, Kuter K, et al. (2004) Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol Dis 17: 219-236.
38. Sgambato-Faure V, Buggia V, Gilbert F, Lévesque D, Benabid AL, et al. (2005) Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats. J Neuropathol Exp Neurol 64: 936-947.
39. Bramham CR, Alme MN, Bittins M, Kuipers SD, Nair RR, et al. (2010) The Arc of synaptic memory. Exp Brain Res 200: 125-140.
40. Huang F, Chotiner JK, Steward O, (2007) Actin polymerization and ERK phosphorylation are required for Arc/Arg3.1 mRNA targeting to activated synaptic sites on dendrites. J Neurosci 27: 9054-9067.
41. Steward O, Worley PF, (2001) Selective targeting of newly synthesized Arc mRNA to active synapses requires NMDA receptor activation. Neuron 30: 227-240.
42. Calabresi P, Giacomini P, Centonze D, Bernardi G, (2000) Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol 47: S60-68.
43. Chase TN, Oh JD, (2000) Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 47: S122-130.
44. Sgambato-Faure V, Cenci MA, (2012) Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Prog Neurobiol 96: 69-86.
45. Castillo PE, Francesconi A, Carroll RC, (2008) The ups and downs of translation-dependent plasticity. Neuron 59: 1-3.